Putney develops and supplies high-quality, cost-effective generic and specialty pharmaceutical medicines for companion animals, including bioequivalent alternatives to branded veterinary drugs. The company seeks to empower veterinarians and pet owners with affordable drug options and a reliable supply to improve compliance with veterinary recommendations. Putney plans to expand its pipeline through product acquisition and licensing, invest in R&D, and hire additional management talent to build out commercial and operational capabilities. Proceeds from its recent financing will be used for product development, to enhance sales and marketing capabilities, and for operational and working capital needs. The company targets a sizable addressable market: APPMA data cited in the filing notes over 60% of U.S. households had companion animals in 2010 and the global companion animal pharmaceuticals market is estimated at $5.6 billion, with many FDA‑approved veterinary drugs lacking generic competition.

Total raised

$21M

Funding rounds

1

Latest round

Series C

Latest activity

Sep 2011